Viral and Immunological Analytes are Poor Predictors of the Clinical Treatment Response in Kaposi's Sarcoma Patients.
HIV-1
KSHV
Kaposi’s sarcoma
T-cells
cytokine
immune responses
neutralizing antibody
sub-Saharan Africa
treatment response
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
16 Jun 2020
16 Jun 2020
Historique:
received:
17
05
2020
revised:
07
06
2020
accepted:
12
06
2020
entrez:
21
6
2020
pubmed:
21
6
2020
medline:
21
6
2020
Statut:
epublish
Résumé
Kaposi's sarcoma-associated herpes virus (KSHV) is the etiologic agent for Kaposi's sarcoma (KS). The prognostic utility of KSHV and HIV-1 (human immunodeficiency virus) viremia as well as immunological parameters in clinical management of participants with KS is unclear. The objective of this study was to investigate viral and immunological parameters as predictors of KS treatment responses in participants with KS from sub-Saharan Africa (SSA). Plasma KSHV-DNA, HIV-1 viral load, total anti-KSHV antibody, KSHV-neutralizing antibody (nAb), cytokine/chemokine levels, and T-cell differentiation subsets were quantified before and after KS treatment in 13 participants with KS and in 13 KSHV-infected asymptomatic control individuals. One-way analysis of variance and the Mann-Whitney t-test were used to assess differences between groups where
Identifiants
pubmed: 32560243
pii: cancers12061594
doi: 10.3390/cancers12061594
pmc: PMC7352224
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : FIC NIH HHS
ID : K43 TW011418
Pays : United States
Organisme : NIH HHS
ID : U54 CA190155
Pays : United States
Organisme : NIH HHS
ID : P30 GM103509
Pays : United States
Organisme : NIH HHS
ID : K43TW011418
Pays : United States
Références
Virology. 2004 Aug 1;325(2):225-40
pubmed: 15246263
N Engl J Med. 2007 Sep 27;357(13):1352-3
pubmed: 17898112
J Infect Dis. 2018 Jan 4;217(2):263-269
pubmed: 29099933
Oncol Lett. 2019 Jan;17(1):1349-1356
pubmed: 30655905
BMC Res Notes. 2015 Sep 15;8:440
pubmed: 26374100
Clin Infect Dis. 2010 Aug 1;51(3):350-8
pubmed: 20583924
Int J Cancer. 2010 Nov 15;127(10):2395-401
pubmed: 20143397
Cell Mol Life Sci. 2018 Feb;75(4):689-713
pubmed: 29032503
Curr Opin Oncol. 2012 Sep;24(5):522-30
pubmed: 22729153
AIDS. 2004 Aug 20;18(12):1737-40
pubmed: 15280789
PLoS One. 2014 Mar 14;9(3):e91020
pubmed: 24632813
Oncotarget. 2015 Oct 6;6(30):30334-42
pubmed: 26296972
J Acquir Immune Defic Syndr. 2012 Apr 15;59(5):447-54
pubmed: 22067664
J Pediatr Hematol Oncol. 2020 Jan;42(1):69-73
pubmed: 30601401
Am J Epidemiol. 2014 Oct 1;180(7):687-95
pubmed: 25167864
Pediatric Health Med Ther. 2018 Apr 19;9:35-46
pubmed: 29722363
Infect Agent Cancer. 2018 Jan 19;13:5
pubmed: 29387144
Int Immunol. 2009 Dec;21(12):1303-9
pubmed: 19819937
Br J Cancer. 1998 Dec;78(11):1521-8
pubmed: 9836488
Clin Infect Dis. 2010 Aug 1;51(3):342-9
pubmed: 20572760
Blood. 2008 Apr 15;111(8):3986-90
pubmed: 18172004
PLoS One. 2013 Aug 14;8(8):e71254
pubmed: 23967174
Arch Pathol Lab Med. 2013 Feb;137(2):289-94
pubmed: 23368874
Clin Infect Dis. 2020 May 23;70(11):2435-2438
pubmed: 31626689
Cytokine. 2015 Jul;74(1):27-34
pubmed: 25481648
J Acquir Immune Defic Syndr. 2000 Apr 1;23(4):361
pubmed: 10836764
J Exp Med. 2009 Jan 16;206(1):69-78
pubmed: 19139170
Biosci Biotechnol Biochem. 2004 Nov;68(11):2279-84
pubmed: 15564665
J Infect Dis. 2019 Apr 8;219(8):1318-1328
pubmed: 30452681
HIV Med. 2016 Jan;17(1):56-61
pubmed: 26111246
J Pathol. 2008 Jan;214(2):179-89
pubmed: 18161751
ISRN AIDS. 2012 May 30;2012:565463
pubmed: 24052878
J Clin Oncol. 2009 May 20;27(15):2496-502
pubmed: 19349542
Pediatr Blood Cancer. 2010 May;54(5):670-4
pubmed: 20205254
mBio. 2017 Oct 10;8(5):
pubmed: 29018115
Trop Doct. 2008 Jan;38(1):5-7
pubmed: 18302849
Oncotarget. 2017 Nov 25;8(65):109402-109416
pubmed: 29312617
J Clin Oncol. 1997 Sep;15(9):3085-92
pubmed: 9294471
Trop Med Int Health. 2015 May;20(5):665-672
pubmed: 25611008
Int J Cancer. 2015 Jun 15;136(12):2822-30
pubmed: 25395177
AIDS. 2010 Nov 27;24(18):2881-3
pubmed: 20827160
Br J Cancer. 2000 May;82(9):1585-92
pubmed: 10789729
Curr HIV Res. 2018;16(3):231-236
pubmed: 29992888
J Acquir Immune Defic Syndr. 2016 Mar 1;71(3):295-301
pubmed: 26452066
Int J Cancer. 1984 Feb 15;33(2):203-12
pubmed: 6319302
J Clin Oncol. 2014 Feb 10;32(5):402-8
pubmed: 24378417
Clin Cancer Res. 2019 Jul 15;25(14):4238-4247
pubmed: 30979736
Immunol Rev. 2002 Aug;186:221-33
pubmed: 12234374
Int J Cancer. 2000 Jan 1;85(1):54-9
pubmed: 10585583